SeaStar Medical Holding (ICU) Net Cash Flow (2021 - 2026)
SeaStar Medical Holding's (ICU) quarterly Net Cash Flow came in at -$2.6 million in Q1 2026, down 175.7% YoY from $3.5 million in Q1 2025, and down 47.62% on a QoQ basis from -$1.8 million in Q4 2025.
SeaStar Medical Holding (ICU) Net Cash Flow (2021 - 2026) Analysis & Trends
SeaStar Medical Holding (ICU) has 6 years of Net Cash Flow data on file, last reported at -$2.6 million in Q1 2026.
- Quarterly Net Cash Flow fell 175.7% year-over-year to -$2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 1362.82% YoY) and the FY2025 annual result came in at $10.2 million, up 518.44% from the prior year.
- Net Cash Flow eased to -$2.6 million in Q1 2026, from -$1.8 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $7.5 million in Q3 2025 to a low of -$3.8 million in Q2 2024.
- A 5-year average of $519882.4 and a median of $60000.0 in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow surged 5250.0% — and 2025, when it slumped 577.95%.
- Tracing ICU's Net Cash Flow over 5 years: stood at -$2000.0 in 2022, then surged by 5250.0% to $103000.0 in 2023, then plunged by 355.34% to -$263000.0 in 2024, then tumbled by 577.95% to -$1.8 million in 2025, then slumped by 47.62% to -$2.6 million in 2026.
- The last three Net Cash Flow figures came in at -$2.6 million (Q1 2026), -$1.8 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | SeaStar Medical Holding | 13.89 Mn | 6.89 Mn | 561,000.00 | -2.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.39 Mn |
| Jun 30, 2026 | -2.39 Mn |
| Mar 31, 2026 | -2.63 Mn |
| Mar 31, 2026 | -2.63 Mn |
| Dec 31, 2025 | -1.78 Mn |
| Dec 31, 2025 | -1.78 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 3.48 Mn |
| Mar 31, 2025 | 3.48 Mn |
| Dec 31, 2024 | -263,000.00 |
| Dec 31, 2024 | -263,000.00 |
| Sep 30, 2024 | 903,000.00 |
| Sep 30, 2024 | 903,000.00 |
| Jun 30, 2024 | -3.84 Mn |
| Jun 30, 2024 | -3.84 Mn |
| Mar 31, 2024 | 4.84 Mn |
| Mar 31, 2024 | 4.84 Mn |